CN106667903A - Fluoxetine tincture for treating leucoderma - Google Patents
Fluoxetine tincture for treating leucoderma Download PDFInfo
- Publication number
- CN106667903A CN106667903A CN201710006871.8A CN201710006871A CN106667903A CN 106667903 A CN106667903 A CN 106667903A CN 201710006871 A CN201710006871 A CN 201710006871A CN 106667903 A CN106667903 A CN 106667903A
- Authority
- CN
- China
- Prior art keywords
- fluoxetine
- tincture
- ethanol
- leucoderma
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Abstract
The invention relates to a fluoxetine tincture for treating leucoderma and a preparation method of the fluoxetine tincture. The fluoxetine tincture contains the following components: fluoxetine hydrochloride, ethanol, glycerin and vitamin C. By utilizing the property that fluoxetine can stimulate the production of melanocyte, fluoxetine is prepared into a tincture medicine, and the tincture medicine has remarkable effects of treating the leucoderma; the leucoderma is easily prepared and low in cost; and the fluoxetine tincture has great economic and social significances.
Description
Technical field
The present invention relates to medical production technical field, more particularly to one kind treats leukodermic fluoxetine tincture.
Background technology
Vitiligo is a kind of pigmentosa Mucocutaneous diseases of agnogenic posteriority, and modal reason is that pigment takes off
Lose, global prevalence is 1%, the prevalence of China is 0.1%~2%.Treating leukodermic method at present has：Drug therapy,
Naturopathy, operative treatment and conjoint therapy.Wherein treating leukodermic medicine has：Corticosteroid hormone, calcium adjust phosphoric acid
Enzyme inhibitor, trace element, vitamin D, Janus kinases（JAK）Inhibitor, the medicine for adjusting cell Redox reaction.Mesh
Before the leucoderma medicament applied for a patent mostly be Chinese prescription.Such as Application No. CN201610713102.7 patent《One kind treatment
Leukodermic Chinese medicine》, the patent of Application No. CN201410235188.8《One kind treats leukodermic Chinese medicine composition》.
Fluoxetine is a kind of selective serotonin reuptake inhibitor, is developed by Lilly Co., Eli., in 20th century
The beginning of the nineties lists, and with good antidepressant effects, is taken as first-line drug to be widely used in clinic at present.Main pharmacological is made
With the reuptake for being the 5-hydroxy tryptamine for optionally suppressing central nervous system's presynaptic to discharge, selective 5- is also called
Hydroxytryptamine reuptake inhibitor.And to other receptors, such as alpha-adrenergic, beta-adrenergic, 5-hydroxy tryptamine energy, dopamine
Can wait, fluoxetine is then almost not bound with power.Latest find fluoxetine can be used for treating vitiligo.
Tincture, tincture mean medicine normal concentration ethanol leach or dissolve and made by supernatant liquid preparation, also may be used
Made with fluid extract dilution, for for oral administration or external.Tincture in vitiligo external used medicine（Alcohol preparation）Occupy great proportion,
Totally stationary phase or convalescent period can be with external-use tinctures, to stimulate melanocyte so as to functional rehabilitation or melanocyte work(
Can be active.
At present leukodermic treatment is still more difficult, and clinical efficacy has very big difference due to individual difference, therefore
Conventional therapy cannot meet the treatment of all patients, for these patients can attempt new Therapeutic Method.
The content of the invention
The present invention is in order to make up the deficiencies in the prior art, there is provided one kind treats leukodermic novel drugs.
The present invention is achieved through the following technical solutions：
One kind of the present invention treats leukodermic fluoxetine tincture, the component comprising following content in every 1000ml medicines：Fluoxetine
50-100mg, 75% ethanol 400-750ml, glycerol 400-500ml, vitamin C 0-200mg.
Component comprising following content in wherein preferably per 1000ml medicines：Fluoxetine 70-100mg, 75% ethanol 500-
600ml, glycerol 400-500ml, vitamin C 100-200mg.
Component comprising following content in more preferably per 1000ml medicines：Fluoxetine 100mg, 75% ethanol 500ml, glycerol
500ml, vitamin C 100mg.
Its preparation method is：
(1) first 100mg vitamin Cs are dissolved in into the ethanol solution of 500ml75%；
(2) 100mg fluoxetine Hydrochlorides are weighed, step is dissolved in（1）In gained mixed solution in, stirring makes fully dissolving；
(3) 500ml glycerol is measured, with step（2）Resulting solution is sufficiently mixed, and obtains settled solution.Loaded in brown bottle.
The invention has the beneficial effects as follows：The present invention provides novel drugs and novel form for leukodermic treatment.Suitable for complete
Full resting stage or convalescent period, melanocyte can be stimulated so as to recover function, effect is significant.
Specific embodiment
Embodiment 1：
100mg vitamin Cs are weighed, vitamin C is added in the ethanol solution of 500ml 75%, be slowly added into, side edged is stirred
Mix, until being completely dissolved；100mg fluoxetine Hydrochlorides are weighed, is added containing in ascorbic ethanol solution, stirred 5 minutes；Measure
500ml glycerol, mixes with above-mentioned solution, and vibration is mixed, and is fitted into sealing preserve in brown bottle.
Embodiment 2：
100mg fluoxetine Hydrochloride solids are weighed, it is stirring while adding in adding it to the ethanol solution of 500ml75% so as to complete
CL, adds 500ml glycerol, and vibration mixing is fitted into sealing preserve in brown bottle.
Claims (6)
1. one kind treats leukodermic fluoxetine tincture, it is characterised in that be prepared into fluoxetine Hydrochloride medicine dissolution in ethanol
Arrive.
2. fluoxetine tincture according to claim 1, it is characterised in that also including following component：
Ethanol, glycerol, vitamin C.
3. according to claim 2, it is characterised in that the concentration of ethanol is 75%.
4. according to claim 3, it is characterised in that the addition of ethanol is 40% ~ 75%.
5. according to claim 2, it is characterised in that the addition 40% ~ 50% of glycerol.
6. according to claim 2, it is characterised in that ascorbic addition is 0 ~ 20%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710006871.8A CN106667903A (en) | 2017-01-05 | 2017-01-05 | Fluoxetine tincture for treating leucoderma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710006871.8A CN106667903A (en) | 2017-01-05 | 2017-01-05 | Fluoxetine tincture for treating leucoderma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106667903A true CN106667903A (en) | 2017-05-17 |
Family
ID=58849961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710006871.8A Pending CN106667903A (en) | 2017-01-05 | 2017-01-05 | Fluoxetine tincture for treating leucoderma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106667903A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375428A (en) * | 2017-07-20 | 2017-11-24 | 山东润泽制药有限公司 | A kind of ointment of Prozac combination traditional Chinese medicine ingredients treatment leucoderma and preparation method thereof |
| CN108969512A (en) * | 2017-06-05 | 2018-12-11 | 南京睿鹰润泽生物医药科技有限公司 | A kind of medical composition and its use of Fluoxetine or racemic fluoxetine salt form |
| WO2020238570A1 (en) * | 2019-05-28 | 2020-12-03 | 南京睿鹰润泽生物医药科技有限公司 | Composition containing fluoxetine and vitamin d 3 or its derivatives, and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102429894A (en) * | 2011-12-07 | 2012-05-02 | 中国药科大学 | Application of fluoxetine to treatment of depigmentation disease |
| CN103381204A (en) * | 2012-05-06 | 2013-11-06 | 田荣侠 | Leucoderma medicament and preparation method thereof |
-
2017
- 2017-01-05 CN CN201710006871.8A patent/CN106667903A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102429894A (en) * | 2011-12-07 | 2012-05-02 | 中国药科大学 | Application of fluoxetine to treatment of depigmentation disease |
| CN103381204A (en) * | 2012-05-06 | 2013-11-06 | 田荣侠 | Leucoderma medicament and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 南京医学院，南京医学院第一附属医院: "《临床药物手册》", 30 October 1986, 上海科学技术出版 * |
| 李圣惠: "积雪草等３种挥发油对盐酸氟西汀体外经皮渗透性的影响", 《南京中医药大学学报》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108969512A (en) * | 2017-06-05 | 2018-12-11 | 南京睿鹰润泽生物医药科技有限公司 | A kind of medical composition and its use of Fluoxetine or racemic fluoxetine salt form |
| CN107375428A (en) * | 2017-07-20 | 2017-11-24 | 山东润泽制药有限公司 | A kind of ointment of Prozac combination traditional Chinese medicine ingredients treatment leucoderma and preparation method thereof |
| WO2020238570A1 (en) * | 2019-05-28 | 2020-12-03 | 南京睿鹰润泽生物医药科技有限公司 | Composition containing fluoxetine and vitamin d 3 or its derivatives, and application thereof |
| JP2022534264A (en) * | 2019-05-28 | 2022-07-28 | ナンジン ルーイン ルンゼ バイオファーマシューティカル テクノロジー カンパニー インコーポレイテッド | COMPOSITION CONTAINING FLUOXETINE AND VITAMIN D3 OR DERIVATIVE THEREOF AND USE THEREOF |
| JP7413619B2 (en) | 2019-05-28 | 2024-01-16 | ナンジン ルーイン ルンゼ バイオファーマシューティカル テクノロジー カンパニー インコーポレイテッド | Composition containing fluoxetine and vitamin D3 or its derivatives and uses thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106667903A (en) | Fluoxetine tincture for treating leucoderma | |
| CN103622903B (en) | Propranolol hydrochloride lipidosome gel and preparation method thereof | |
| CN101623291B (en) | Dexamethasone sodium phosphate injection | |
| CN103070914A (en) | Traditional Chinese medicine composition for treating rhinitis and preparation method thereof | |
| CN102068494B (en) | Health-care capsules with treatment effect on chemical liver injury and preparation method thereof | |
| JPH10158169A (en) | Pharmaceutical preparation containing trospium chloride, its preparation and use thereof | |
| JP5839362B2 (en) | Methods and compositions for treating or preventing symptoms of hormonal fluctuation | |
| WO2014118040A1 (en) | Extract from indigo tinctoria for the topical treatment and prophylaxis of skin disorders | |
| CN105168119A (en) | Compound nasal inhalation gel preparation for treating rhinitis | |
| CN102166219A (en) | Nasal administration preparation and application thereof | |
| CN101991561B (en) | 3,4-dichlorophenyl-propenoyl-sec-butylamine composition | |
| CN104825416A (en) | Disulfiram implant and preparation method thereof | |
| CN111150722A (en) | Astaxanthin preparation for resisting virus | |
| CN102133175B (en) | Amygdalin gel and preparation method and medicinal application thereof | |
| CN104940181B (en) | The purposes of β hydroxybutyric acids or its pharmaceutically acceptable salt | |
| CN103690473B (en) | A kind of sinomenine preparation and preparation method thereof | |
| CN1771937A (en) | Externally applied podophyllotoxin ointment and its prepn | |
| CN101450051B (en) | Monomer salvianolic acid B injection and preparation method thereof | |
| CN106491523A (en) | A kind of Bu Waxitan oral administration solutions and preparation method thereof | |
| AU2016256704B2 (en) | Pharmaceutical composition increasing cyclic AMP content and availability in vivo, and preparation method thereof | |
| CN101683510A (en) | Chinese medicine patch for treating cold and pain and method for producing the same | |
| CN102973563A (en) | Application of ombination of esveratrol and piperine used for preparation of medicament for treatment of depression | |
| CN102697703A (en) | Piroxicam gel preparation and preparation method thereof | |
| CN109528708A (en) | Application of the Kaempferol in preparation treatment rhinitis drug | |
| CN109718230A (en) | Application of the salviandic acid A in preparation inhibiting hyperuricemia and anti-gout drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170517 |
|
| WD01 | Invention patent application deemed withdrawn after publication |